CASE REPORT

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report

Guotian Pei1, Shanbo Cao2 & Yuqing Huang1

1 Department of Thoracic Surgery, Beijing Haidian Hospital, Haidian Section of Peking University Third Hospital, Beijing, China
2 Acornmed Biotechnology Co., Ltd, Beijing, China

Keywords
Intrapulmonary metastasis; molecular analysis; multiple primary lung cancer.

Correspondence
Yuqing Huang, Department of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), No 29, Zhongguancun Street, Haidian District, Beijing, 100080, China.
Tel: +86 8269 3152;
Fax: +86 10 6264 6336;
Email: huangyuqing555@gmail.com;
Received: 9 July 2020;
Accepted: 25 July 2020.
doi: 10.1111/1759-7714.13618

Thoracic Cancer 11 (2020) 3020–3023 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract
Multiple primary lung cancer (MPLC) is defined as two or more primary lung cancers occurring in the same patient and can be classified as synchronous multiple primary lung cancer (sMPLC) and metachronous multiple primary lung cancer (mMPLC). Due to various clinicopathological characteristics and genetic features, MPLC is increasingly encountered in clinical practice. The distinction between MPLC and intrapulmonary metastasis (IM) is of great importance to clinical treatment and prognosis. However, there are currently no golden diagnostic criteria for MPLC due to tumor heterogeneity. Here, we report the case of a patient with four lung cancers (tumor 1, named T1, in the right middle lobe seven years earlier; tumor 2, named T2, in the left lower lobe; tumor 3 and tumor 4, named T3 and T4, in the left upper lobe) and two tumors (T1 and T2) which shared the mutation in epidermal growth factor receptor (EGFR) L858R/T790M, which indicate that these two tumors might have originated from a common ancestor. However, these three tumors (T2–T4) were diagnosed as mMPLC based on previously published guidelines, these three tumors (T2T4) were diagnosed as mMPLC.

Introduction
Multiple primary lung cancer (MPLC) refers to the synchronous or metachronous occurrence of two or more primary lung cancers in a single patient, which can be further divided into synchronous MPLC (sMPLC) and metachronous MPLC (mMPLC) based on the time of occurrence. With the increased availability of high-resolution computed tomography (CT) and lung cancer screening programs, the reported MPLC incidence rate has been increasing in recent years.1

Although the diagnostic criteria for MPLC have been greatly improved, there are currently no golden diagnostic criteria for of MPLC. We herein report the case of a patient with four lung cancers (tumor 1–tumor 4) and two tumors (tumor 1 and tumor 2) which shared the mutation in epidermal growth factor receptor (EGFR) L858R/T790M, and which indicate that these two tumors might have originated from a common ancestor. However, these three tumors (T2–T4) were diagnosed as mMPLC based on the current diagnostic criteria. The following case is presented in accordance with the CARE reporting checklist.

Case report
A 49-year-old Chinese woman who was a never smoker was admitted to the Department of Thoracic Surgery of Beijing Haidian Hospital on 13 November 2019 after multiple pulmonary nodules including two nodules in the left upper lobe and one nodule in the left lower lobe had been detected during a health examination (Fig 1). Her physical examination was unremarkable. No distant metastases were found on routine examination. According to the patient, she was diagnosed with stage IIb (pT1N1M0) poorly differentiated lung adenocarcinoma (mixed subtype) in the right middle lobe (tumor 1, named T1) which was treated with right middle lobectomy and followed by four cycles of pemetrexed-cisplatin chemotherapy (pemetrexed 500 mg/m2 day 1, cisplatin 75 mg/m2 day 1, for 21 days as a cycle) seven years previously.
She then underwent wedge resections of the left upper lobe and left lower lobe and lymph node dissection by video-assisted thoracoscopic surgery (VATS). The postoperative pathological subtype of each lesion was acinar predominant adenocarcinoma (tumor 3, named T3) and atypical adenomatous hyperplasias (tumor 4, named T4) in the left upper lesion and minimally invasive adenocarcinoma (tumor 2, named T2) in the left lower lesion. No lymph node metastasis was observed. Next-generation sequencing (NGS) test for a large panel containing 808 oncogenic genes was used for molecular testing of all available tumor and matched blood samples (Fig 2).

We found that three lesions (T1, T2 and T3) shared a single mutation in *EGFR* L858R. The lesions T1 and T3 displayed different major histological subtypes and were therefore considered as separate primary lung cancers. No shared mutations were identified between lesion T4 and other lesions, and we concluded that T4 was from an independent clonal origin. Interestingly, the lesions T1 and T2 shared the mutation in *EGFR* L858R/T790M (Fig 2), suggesting that these two lesions might have originated from a common ancestor. However, based on the Martini and Melamed criteria or the American College of Chest Physicians (ACCP) guidelines, these three lesions (T2-4) were diagnosed as mMPLC (pT1bN0M0, stage...
IA2). Because the tumors were still at an early stage, the patient did not receive adjuvant therapy but continued to be monitored through regular hospital visits every three months. To date, no recurrence or metastasis was found in this patient (Fig 3).

**Discussion**

With advances in imaging technology, MPLC is increasingly encountered in clinical practice. The accurate diagnosis and treatment of MPLC has become an urgent concern. However, it is difficult to distinguish the second primary lesion and the metastasis. In 1924, Beyreuther described cases of “double primary lung cancer” and introduced the concept of MPLC for the first time. The clinicopathological criteria for the diagnosis of MPLC was established by Martini and Melamed in 1975 and then revised by Antakli et al. and Colice et al. who extended the required disease-free interval up to four years. However, this empirical classification did not include molecular analysis, which is now routinely performed for lung adenocarcinoma. The ACCP guidelines then developed the diagnostic criteria with further clinical evaluations including histological subtypes of adenocarcinoma and molecular genetic characteristics. Although the diagnostic criteria have been greatly improved, the diagnosis and classification of MPLC has still not reached consensus amongst the Union for International Cancer Control (UICC), American Joint Committee on Cancer (AJCC), and International Association for the Study of Lung Cancer (IASLC). Nowadays, recent studies have revealed that comprehensive molecular analysis are playing important roles in the differentiation of MPLC and IM. In general, tumors with largely concordant mutations have been considered as clonal in origin (metastases), and those with discordant mutations considered to be primary tumors. However, the same mutations may occur in morphologically different tumors and driver mutations, especially for EGFR germline mutation, which can also complicate the interpretation of the clonal relationship of multiple lung adenocarcinoma. Therefore, significant caution is advised when interpreting the same mutations in two tumors.

In this report, our patient was an unusual case with early-stage metachronous multiple lung cancers and treatment-naïve EGFR L858R/T790M mutations in two tumors seven years after right middle lobectomy. How do we explain this phenomenon? On the one hand, these three tumors (T2–T4) could be diagnosed as mMPLC based on the current diagnostic criteria. On the other hand, treatment-naïve NSCLC with EGFR T790M mutation is rare, and has only been reported in around 2% of patients with EGFR-mutant lung cancer. Furthermore, concurrent mutations in EGFR L858R/T790M have been reported in around 0.5% of EGFR mutation-positive patients before exposure to EGFR-tyrosine kinase inhibitors (TKIs). In this report, T1 and T2 shared the EGFR L858R/T790M mutation, suggesting that these two lesions might have originated from a common ancestor. However, despite being provided with all this evidence, we were unsure whether T2 was an IM or not, and it was determined that the results needed to be combined with the patient’s prognosis in order to make an accurate judgment. Long-term follow-up and survival data would also be critical in substantiating our observations.

This is the first case, to our knowledge, of metachronous lung adenocarcinoma harboring EGFR L858R/T790M mutations in a treatment-naïve non-small lung cancer (NSCLC) patient. Comprehensive clinical and molecular analysis may be helpful in differentiating MPLC from...
IM. Due to the ambiguous criteria for the diagnosis of MPLC, more emphasis should be placed on this in future studies.

**Disclosure**

Shanbo Cao is an employee of Acornmed Biotechnology Co., Ltd. All other authors have nothing to disclose.

**References**

1. Asamura H. Multiple primary cancers or multiple metastases, that is the question. *J Thorac Oncol* 2010; 5: 930–1.
2. Martini N, Melamed MR. Multiple primary lung cancers. *J Thorac Cardiovasc Surg* 1975; 70: 606–12.
3. Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS, American College of Physicians. Lung cancer. Special treatment issues. *Chest* 2003; 123: 244S–58S.
4. Kozower BD, Larner JM, Detterbeck FC et al. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013; 143: e369S–99S.
5. Shen KR, Meyers BF, Larner JM, Jones DR. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007; 132: 290S–305S.
6. Beyreuther H. Multiplicität von Carcinomen bei einem Fall von sog. “Schneeberger” Lungenkrebs mit Tuberkulose. *Virchows Arch* 1924; 250: 230–43.
7. Antalki T, Schaefer RF, Rutherford JE, Read RC. Second primary lung cancer. *Ann Thorac Surg* 1995; 59: 863–6; discussion 867.
8. Colice GL, Rubins J, Unger M et al. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. *Chest* 2003; 123: 272S–83S.
9. Warth A, Muley T, Meister M et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. *J Clin Oncol* 2012; 30: 1438–46.
10. Fonseca A, Detterbeck FC. How many names for a rose: Inconsistent classification of multiple foci of lung cancer due to ambiguous rules. *Lung Cancer* 2014; 85: 7–11.
11. Giroux DJ, Rami-Porta R, Chansky K et al. The IASLC lung cancer staging project: Data elements for the prospective project. *J Thorac Oncol* 2009; 4: 679–83.
12. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung: Impact on management and prognosis. *Ann Diagn Pathol* 2001; 5: 321–9.
13. Girard N, Deshpande C, Azzoli CG et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: Comparison with clinical guidelines. *Chest* 2010; 137: 46–52.
14. Arai J, Tsuchiya T, Oikawa M et al. Clinical and molecular analysis of synchronous double lung cancers. *Lung Cancer* 2012; 77: 281–7.
15. Lin MW, Wu CT, Kuo SW, Chang YL, Yang PC. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: Implication for surgical treatment of an uncommon lung malignancy. *Ann Surg Oncol* 2014; 21: 2555–62.
16. Vignot S, Frampton GM, Soria JC et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. *J Clin Oncol* 2013; 31: 2167–72.
17. Gazdar A, Robinson L, Oliver D et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. *J Thorac Oncol* 2014; 9: 456–63.
18. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. *Ann Oncol* 2014; 25: 423–8.
19. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. *N Engl J Med* 2005; 352: 2136.